Image courtesy of Bayer

Bayer invests USD 50 Million in eGenesis Series B financing round

Originally posted on Bayer.com

Investment to support development of human-compatible xeno organs to address the global organ shortage crisis / eGenesis with lead program in kidney transplantation

Bayer Photo
Research in the eGenesis laboratory, Cambridge, MA, USA

Leverkusen, Germany and Boston, Mass., November 7, 2019 – eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures (FMCV), with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors, including, but not limited to, ARCH Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures, all participated.

eGenesis is committed to helping solve the global organ shortage by pioneering an alternative source of human-compatible organs. It is currently estimated that there are between 1.5 to 2 million people on the organ transplant waitlist globally. This financing will enable the acceleration of the eGenesis kidney xenotransplant program into the clinic, as well as support advancement of a range of other xenotransplant programs across islet cell, liver, heart, and lung. The focus of the company is to rapidly advance an entirely new set of options across the transplantation field.

“Leaps by Bayer” is built for the specific purpose of tackling fundamental breakthrough solutions in the fields of health and nutrition with the help of new technologies. Sustainable organ replacement is one of the ten areas of engagement and investment (called “leaps”) for Leaps by Bayer. “We believe eGenesis is poised to revolutionize the entire organ transplantation market. This could save lives in a way that was previously not thought possible just a few years ago,” noted Jürgen Eckhardt, Head of Leaps by Bayer. Eckhardt and Dr. Lucio Iannone will represent Leaps by Bayer by actively participating on the eGenesis Board of Directors.

“eGenesis has a bold vision to solve the organ shortage crisis through xenotransplantation,” said Paul Sekhri, president and chief executive officer of eGenesis. “As we look ahead, we are proud to partner with Leaps by Bayer who has demonstrated a commitment for ushering in paradigm-shifting advances in the life sciences that will bring forward tomorrow’s medicines.”

Kemal Malik, Member of the Board of Management, Bayer AG, and responsible for Innovation, added, “Within Bayer’s innovation strategy, Leaps is driving breakthrough invention at Bayer and the eGenesis approach represents a truly transformational option, addressing the unmet medical need of patients suffering from a disease where organ transplantation could be a potentially lifesaving treatment.”

Leaps by Bayer, a unit of Bayer is investing into solutions to some of today’s biggest challenges in health and agriculture. Previous Leaps investments into potentially breakthrough technologies include Casebia Therapeutics (Cure genetic diseases), BlueRock Therapeutics (Regenerate lost tissue function), Joyn Bio (Reduce environmental impact of farming) as well as Khloris, Century Therapeutics and Pyxis Oncology (Prevent and cure cancer).

Latest News

Abbott Receives CE Mark for Next-Generation Mitraclip Heart Valve Repair Device to Treat Mitral

Originally posted on Abbott.com – CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology – MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip’s history as a safe and…

Cox Crews Mobilized to Reconnect Gulf Coast

Originally published on Cox.com Cox has mobilized its employees with support from outside of the Gulf Coast area to begin assessing damage and restoring service outages caused by Hurricane Sally. In times like this, we understand it is important to stay connected and we want our services to help you…

BASF Invests Into Pyrum as Part of its ChemCyclingTM Project

Originally published on BASF.com  Pyrolysis oil from waste tires as additional raw material source next to oil from mixed plastic waste Investment will support construction of additional production capacities for pyrolysis oil Milestone in establishing a circular economy for post-consumer plastic waste Pyrolysis oil will partly replace fossil feedstock and…

Sanofi and GSK will Provide up to 300 Million doses of COVID-19 vaccine to the European Union

Originally published on sanofi.com. Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union Agreement signed today supports scale-up of manufacturing capabilities in several European countries Vaccine candidate uses Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system Sanofi and GSK finalized…

ICE, whistleblower hysterectomies, COVID

ICE Whistleblower Alleges Unnamed Doctor Performing Hysterectomies, Denying COVID Tests to Detainees

At Immigration and Customs Enforcement (ICE) detainment centers, undocumented detainees are being subjected to “questionable” hysterectomies and are being denied COVID tests, according to a whistleblower. Dawn Wooten, a nurse who worked at the Irwin County Detention Center in Ocilla, GA recently filed a whistleblower complaint alleging medical neglect. A…